Breast cancer could be detected up to five years before there are any clinical signs of it, using a blood test that identifies the body’s immune response to substances produced by tumour cells, according to new research presented at the 2019 NCRI Cancer Conference today (Sunday).
Cancer cells produce proteins called antigens that trigger the body to make antibodies against them – autoantibodies. Researchers at the University of Nottingham (UK) have found that these tumour-associated antigens (TAAs) are good indicators of cancer, and now they have developed panels of TAAs that are known already to be associated with breast cancer to detect whether or not there are autoantibodies against them in blood samples taken from patients.
In a pilot study the researchers, who are part of the Centre of Excellence for Autoimmunity in Cancer (CEAC) group at the School of Medicine, University of Nottingham, took blood samples from 90 breast cancer patients at the time they were diagnosed with breast cancer and matched them with samples taken from 90 patients without breast cancer (the control group).
They used screening technology (protein microarray) that allowed them to screen the blood samples rapidly for the presence of autoantibodies against 40 TAAs associated with breast cancer, and also 27 TAAs that were not known to be linked with the disease.
Presenting the research at the NCRI Conference, Ms Daniyah Alfattani, a PhD student in the group, said: “The results of our study showed that breast cancer does induce autoantibodies against panels of specific tumour-associated antigens. We were able to detect cancer with reasonable accuracy by identifying these autoantibodies in the blood.”
The researchers identified three panels of TAAs against which to test for autoantibodies. The accuracy of the test improved in the panels that contained more TAAs. The panel of five TAAs correctly detected breast cancer in 29% of the samples from the cancer patients and correctly identified 84% of the control samples as being cancer-free. The panel of seven TAAs correctly identified cancer in 35% of cancer samples and no cancer in 79% of control samples. The panel of nine antigens correctly identified cancer in 37% of cancer samples and no cancer in 79% of the controls.
“We need to develop and further validate this test,” said Ms Alfattani. “However, these results are encouraging and indicate that it’s possible to detect a signal for early breast cancer. Once we have improved the accuracy of the test, then it opens the possibility of using a simple blood test to improve early detection of the disease.”
The researchers are now testing samples from 800 patients against a panel of nine TAAs, and they expect the accuracy of the test to improve with these larger numbers.
“A blood test for early breast cancer detection would be cost effective, which would be of particular value in low and middle income countries. It would also be an easier screening method to implement compared to current methods, such as mammography,” said Ms Alfattani.
The researchers estimate that, with a fully-funded development programme, the test might become available in the clinic in about four to five years.
A similar test for lung cancer is currently being tested in a randomised controlled trial in Scotland, involving 12,000 people at high risk of developing lung cancer because they smoke. They have been randomised to have (or not) an autoantibody blood test called ELISA (Early CDT-Lung). Participants who test positive for the autoantibodies are then followed up with a CT scan every two years in order to detect lung cancer in its early stages when it is easier to treat.
The CEAC group is also working on similar tests for pancreatic, colorectal and liver cancers. Solid tumours like these, as well as lung and breast cancer, represent around 70% of all cancers.
“A blood test capable of detecting any of these cancers at an early stage is the over-riding objective of our work,” concluded Ms Alfattani.
Dr Iain Frame, CEO of NCRI said: “Early diagnosis using simple, non-invasive ways of detecting the first signs of cancer is a key strategic priority for NCRI and something we’d all like to see working in practice. The results from this pilot study for a blood test to detect early breast cancer are promising and build on this research group’s expertise in other cancers, such as lung cancer. It’s obviously early days but we look forward to seeing the results from the larger group of patients that are now being investigated.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- ENHERTU® Approved in the U.S. for the Treatment of Patients With Previously Treated HER2 Positive Advanced Gastric Canceron January 15, 2021 at 4:45 pm
Jan 15, 2021-- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU ® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult ...
- Vera Bradley Foundation for Breast Cancer announces 2021 Classic events scheduleon January 15, 2021 at 4:09 pm
The Vera Bradley Foundation for Breast Cancer announced Friday that its signature Vera Bradley Foundation for Breast Cancer Classic fundraiser will be held Sept. 17 – Sept. 20.
- Woman with stage 4 breast cancer urges change in vaccine priority liston January 15, 2021 at 3:51 pm
A Cornelius woman living with stage 4 breast cancer is urging state leaders to revisit North Carolina’s COVID-19 vaccine distribution priority list.
- Airfield Supply Co. And Kiva Confections Launch Breast Cancer Awareness Campaignon January 15, 2021 at 2:36 pm
Two California-based companies have partnered up to launch a statewide campaign for breast cancer awareness, prevention, and research.
- Free Breast Cancer Screenings Offered For Uninsured Womenon January 15, 2021 at 12:04 pm
The YMCA of Metropolitan Los Angeles and a medical imaging company kicked off a six-week effort Friday offering free breast cancer mammography screenings for uninsured women.
- Buddy to Buddy: The state of breast cancer in 2021on January 15, 2021 at 9:32 am
As we enter a new year, here is a look at the status of breast cancer in the United States according to the American Cancer Society... First some basic stats. About one in eight women in the U.S, or ...
- Vitamins and Supplements to Take After Breast Cancer Treatmenton January 15, 2021 at 8:50 am
Should I take a vitamin or supplement after breast cancer treatment? Which ones are best? Are they safe? Are there any to avoid? Can they prevent breast cancer from coming back? Learn about ...
- Taking aspirin three times a week boosts chances of beating breast and bladder cancer by up to a third, study findson January 15, 2021 at 8:25 am
Researchers from the National Cancer Institute in the United States have revealed that aspirin can improve survival rates for some cancers, including bladder and breast.
- How This Actress Is Helping Breast Cancer Survivors Connect During the Pandemicon January 15, 2021 at 8:09 am
Actress Angela Trimbur—who has appeared in shows like The Good Place, and is the founder of the now defunct LA Municipal Dance Squad—is one such creative, offering a virtual space for breast cancer ...
- Triggering tumor antiviral immune response in triple negative breast canceron January 14, 2021 at 8:02 am
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell ...
via Bing News